J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R A Swift3 and R A Vescio10 1Department of Hematology/Oncology, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA 2Oncotherapeutics, West Hollywood, CA, USA 3James R Berenson, MD, Inc., West Hollywood, CA, USA 4Department of Medical Oncology and Hematology, Central Coast […]
Tag Archives: bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
- What Is Multiple Myeloma?
-
Video Updates
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes in Multiple Myeloma Patients Evaluated
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
March 5, 2017
0 Comments